Biomerieux S A Unsp/Adr (BMXXY) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the BioMariu 2025 Third Quarter Sales Conference Call. The call will be structured in two parts. First, a presentation by BioMariu Group Management Team. Afterwards, there will be a Q&A session. During this session, you may ask question in two ways, by submitting a written question in the box below the player, or by joining the conference call and dial pound key 5 on your telephone keypad to enter the queue. I will now hand over to Emerick Fichet, VP Investor Relations. Please go ahead. Thanks. Hello, everyone. Good afternoon. Good morning. And thank you for joining this call. I'm with Pierre Boulu, CEO, together with Guillaume Vour, CFO. Please note that this conference call will include forward-looking statements that may change or be modified due to uncertainties and risks related to the company's environment. Accordingly, we cannot give any assurance as to whether we will achieve this objective. I also remind you that today's call is recorded and that the replay will be available on our website www.biomérieux-finance.com. I will now end the call over to Claire and then we will open the call to questions. Claire? Good, hello everyone, good morning, good afternoon. So I start with giving you the highlights for the year 2025. So I start with the sales numbers. We've reached a very important milestone, 4 billion euro company now, BioMérieux, growing 6.2% organically, significantly outpacing a market that we're seeing growing around 1% when we look at the diagnostics results from most competitors. This growth would have been 7.8% excluding China. What is very positive within the performance for 2025 is we've made a very profitable growth, reaching 17.9% of our sales, contributing EBIT, and growing 16% organically. And finally, on the numbers side, very stro...